TIDMONC
RNS Number : 0473G
Oncimmune Holdings PLC
22 July 2021
22 July 2021
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Paper validates the ImmunoINSIGHTS Infectious Diseases service
in COVID-19
Paper reveals a remarkable sex-specific prevalence and
selectivity of autoantibody responses to SARS-CoV-2
Oncimmune Holdings plc (AIM: ONC.L), the leading global
immunodiagnostics group, is pleased to announce the pre-publication
of the first results from its collaboration with Cedars-Sinai
Medical Center in Los Angeles, entitled: "Paradoxical Sex-Specific
Patterns of Autoantibodies Response to SARS-CoV-2 Infection"(1) .
The paper focuses on the characterisation of sex-specific
prevalence and selectivity of autoantibody responses to the
SARS-CoV-2 virus.
Since the beginning of the COVID-19 pandemic, there has been an
unprecedented number of initiatives from the life sciences industry
and research institutions to understand and respond to the effects
of COVID-19, but despite first generation vaccines now being
deployed to fight the disease, the need to expand our understanding
of the immune response to SARS-CoV-2 still exists. The results of
this study demonstrate the potential of the SeroTag(TM) Infectious
Diseases discovery array to enable a better understanding of how
SARS-CoV-2 stimulates the immune reaction and predicts responses to
vaccines and therapeutics against the virus.
The aim of this initial research project was to use the SeroTag
Infectious Diseases discovery array to detect autoantibodies to
over 90 antigens previously linked to a range of classic autoimmune
diseases. The researchers sought to comprehensively examine the
diversity of autoantibody responses in male and female health care
workers who were exposed to SARS-CoV-2 and were asymptomatic, or
experienced minor symptoms.
The paper reveals a remarkable sex-specific prevalence and
selectivity of autoantibody responses to SARS-CoV-2 and concludes
that further understanding of the nature of triggered and
persistent autoantibody activation among men and women exposed to
SARS-CoV-2 will be essential for developing effective interventions
against both acute, and chronic immune-mediated sequelae of
COVID-19.
Dr Adam M Hill, CEO of Oncimmune said: "Our work with
Cedars-Sinai Medical Center is developing very novel insights that
will have an important bearing on the management of both short, and
long term sequelae of the disease. I am delighted that the earliest
work packages from our ImmunoINSIGHTS Infectious Disease panel are
now being translated into scientific publications, contributing to
the knowledge base in order to improve clinical outcomes from the
disease. I look forward to reading more from this most active of
collaborations shortly."
(1) https://www.medrxiv.org/content/10.1101/2021.07.15.21260603v1
For further information:
Oncimmune Holdings plc
Dr Adam M Hill, Chief Executive Officer
Matthew Hall, Chief Financial Officer
contact@oncimmune.co.uk
Zeus Capital Limited (Nominated Adviser and Joint Broker)
Andrew Jones, Daniel Harris, Victoria Ayton
+44 (0)20 3829 5000
Singer Capital Markets (Joint Broker)
Aubrey Powell, Harry Gooden, Iqra Amin, James Fischer
+44 (0)20 7496 3000
WG Partners (Joint Broker)
David Wilson, Nigel Barnes, Nigel Birks
+44 (0)203 705 9321
Media enquiries:
FTI Consulting
Ben Atwell, Michael Trace, Alex Davis
Oncimmune@fticonsulting.com
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a leading immunodiagnostics developer, primarily
focused on the growing fields of immuno-oncology, autoimmune
disease and infectious diseases. Oncimmune has a diversified and
growing revenue from its portfolio of diagnostic products to detect
early-stage cancer and a contract discovery and development
service-based platform, delivering actionable insights into
therapies to its pharmaceutical and biotech partners .
Our understanding of the immune system enables us to harness its
sophisticated response to disease to detect cancer earlier and to
support the development of better therapies. The key to improving
cancer survival is early detection and better selection for
therapy. As a company, we are driven by our passion to improve
cancer survival and to give people extra time.
Oncimmune's ImmunoINSIGHTS platform enables life science
organisations to optimise drug development and delivery, leading to
more effective targeted as well as safer treatments for patients.
Oncimmune's immunodiagnostic technology, EarlyCDT, can detect and
help identify cancer on average four years earlier than standard
clinical diagnosis. Our lead diagnostic test, EarlyCDT Lung,
targets a vast market estimated to grow to GBP3.8bn by 2024. With
over 200,000 tests already performed for patients worldwide and its
use being supported by peer reviewed data in over 12,000 patients,
we are poised to become an integral component of future lung cancer
detection programmes, globally.
Oncimmune, headquartered at its laboratory facility in
Nottingham, UK, and has a discovery research centre in Dortmund,
Germany.
For more information, visit www.oncimmune.com
What is ImmunoINSIGHTS?
The ImmunoINSIGHTS service business leverages Oncimmune's
technology platform and methodologies across multiple diseases, to
offer life-science organisations actionable insights for therapies
across the development and product lifecycle. Our core
immune-profiling technology is underpinned by our library of over
eight thousand immunogenic proteins, one of the largest of its
kind. This helps identify trial participants and patients into
clinically relevant subgroups, enabling development of targeted and
more effective treatments.
What is SeroTag?
Oncimmune's proprietary biomarker discovery engine, which is
leveraged in our ImmunoINSIGHTS services to discover and validate
novel biomarkers can help stratify patients in multiple cancer
indications and with different autoimmune diseases.
This high-throughput, multiplex technology is based on one of
the largest, in-house protein libraries, as well as a unique,
ever-growing repository of disease data for indications including,
but not limited to, autoimmune diseases and cancer. As a result,
SeroTag is helping to address and monitor a number of challenges
currently hindering the successful development and broader
application of both cancer immunotherapies and treatments for
autoimmune diseases.
The platform is being applied to discover and validate
biomarkers and develop precision diagnostic tools from minimally
invasive liquid biopsies. SeroTag analyses autoantibodies-some of
the most stable analytes-and is used most frequently for the
identification of IgG isoforms, in addition to IgM and IgA, from
just a few drops of serum.
The SeroTag platform acts as the primary discovery engine that
feeds into the creation of Oncimmune's NavigAID disease-specific
stratification panels-precision medicine tools which are enabling
patient and disease stratification and support therapeutic
development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPUQCMUPGGQG
(END) Dow Jones Newswires
July 22, 2021 02:00 ET (06:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2023 to Apr 2024